**Covidh Technologies Limited** (BSE: **534920**) is an Indian listed entity currently undergoing a transformative revival and strategic pivot. Following a court-approved restructuring under the **Insolvency and Bankruptcy Code (IBC)** in **February 2024**, the company is transitioning from a period of operational dormancy toward a new core focus in the **Life Sciences and Healthcare** sectors. The company is currently managed under a new promoter group following a significant change in control and a series of capital-raising initiatives intended to stabilize its financial position and meet regulatory listing requirements. --- ### **Strategic Pivot: Transition to iSERA Lifesciences** The company is executing a fundamental shift in its business identity and industry focus, moving away from its legacy IT roots toward high-growth medical sectors. * **Corporate Rebranding:** In **April 2026**, the company approved a name change to **iSERA Lifesciences Limited** to align its corporate identity with its new strategic direction. * **Major Acquisition:** The company executed a non-binding Letter of Intent (LOI) in **February 2026** to acquire **100% equity shareholding** of **iSERA Biological Limited**, marking its formal entry into the life sciences space. * **Geographic Relocation:** To support its expanded business operations and market reach, the company shifted its Registered Office from **Hyderabad, Telangana** to **Pune, Maharashtra** in **February 2026**. * **New Leadership:** The appointment of **Mr. Dhairyasheel Vasantrao Yadav** and **Mr. Nandkumar Subhash Kadam** as Executive Directors in **April 2026** signals a shift toward management with expertise in scaling medical and life science ventures. --- ### **Legacy IT/ITES Service Portfolio** While the company pivots toward life sciences, it maintains a comprehensive framework for technology-enabled services, which provided the foundation for its initial revival: * **Software & Web Solutions:** End-to-end design, development, customization, and cloud/data center hosting. * **IT-Enabled Services (ITES):** Call center operations, medical and legal transcription, and back-office functions. * **Infrastructure & Hardware:** Data center management, IT consultancy, and the manufacturing/trading of computer peripherals and network systems. * **Human Capital Services:** Staffing solutions, HR consultancy, and IT training institutions. * **Target Verticals:** Government & Public Sector, Healthcare, Financial Services, Manufacturing, and Retail. --- ### **Capital Restructuring & Ownership Evolution** The company’s capital structure has been significantly reconstructed to exit insolvency and comply with **SEBI’s Minimum Public Shareholding (MPS)** requirements. | Event | Date | Impact/Details | | :--- | :--- | :--- | | **IBC Resolution Plan** | **Feb 20, 2024** | Approved by **NCLT**; involved cancellation of old promoter shares and allotment of **3,00,000** shares to new promoter **Mr. Ganapa Narsi Reddy**. | | **Rights Issue** | **Oct/Nov 2025** | Raised **₹8.09 crore** via **80,85,550** shares at **₹10 per share** to fund working capital and meet MPS. | | **Open Offer** | **Jan 2026** | Acquirers (9 Strategic Investors) sought **21,86,333** shares (**26%** of capital) at **₹10 per share** for management control. | | **Promoter Exit** | **2026** | **Mr. Ganapa Narsi Reddy** renounced rights and will be re-classified as a public shareholder; control passed to the **Acquirer Group**. | **Current Capital Snapshot:** * **Authorized Share Capital:** **₹11,00,00,000** (1.10 crore shares of **₹10** each). * **Listing Status:** Listed on **BSE**; currently monitored under **GSM Stage 0** and **ESM Stage 2**. --- ### **Financial Performance & Working Capital Targets** Post-revival, the company has reported its first signs of operational activity, though it remains in the early stages of financial recovery. **Comparative Financial Summary (₹ in Lakhs):** | Particulars | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Revenue from Operations** | **26.52** | **0.00** | | **Profit Before Tax (PBT)** | **13.90** | **(9.89)** | | **Profit After Tax (PAT)** | **(11.81)** | **(9.89)** | | **Operating Cash Flow** | **140.00** | **6.07** | **Efficiency Targets for FY 2025-26:** The company has established aggressive targets to optimize its liquidity cycle as it scales: * **Trade Receivable Cycle:** Target reduction from **180 Days** to **150 Days**. * **Trade Payable Cycle:** Target reduction from **20 Days** to **15 Days**. --- ### **Use of Capital & Future Investments** The net proceeds from recent capital raises (**₹708.56 lakhs**) are strategically allocated to facilitate growth: 1. **Working Capital (₹506.42 lakhs):** Dedicated to supporting staffing and longer receivable cycles inherent in government and consulting contracts. 2. **General Corporate Purposes (₹202.14 lakhs):** Allocated for CAPEX, facility refurbishment, and unforeseen exigencies. 3. **Strategic Tech Investment:** A potential allocation of **₹4.31 crore** has been identified for a joint venture or subsidiary focusing on **AI, Blockchain, or Cybersecurity** to augment its life sciences pivot. --- ### **Critical Risk Factors & Challenges** **Operational & Financial Risks:** * **Execution & Diversification:** The company is moving into the unfamiliar medical/life sciences sector; success depends on the integration of **iSERA Biological Limited**. * **Insurance Deficit:** As of late **2025**, the company maintains **no insurance coverage** for assets, personnel, or cyber liabilities, representing a significant risk of catastrophic loss. * **Resource Constraints:** The company lacks formal credit facilities and relies on equity infusions. Key leadership positions, including the **Chief Financial Officer (CFO)**, have historically seen vacancies. **Regulatory & Compliance Risks:** * **Listing History:** Trading was previously suspended for **non-payment of Annual Listing Fees (2022-23)**. While restored, the company remains under enhanced surveillance (ESM). * **MPS Compliance:** If the Open Offer results in public shareholding falling below **25%**, the new acquirers must implement a compliance plan to maintain listing status. * **Permit Renewals:** Many statutory licenses expired during the **CIRP** period and are currently in the process of renewal. **Market & Industry Risks:** * **Customer Concentration:** Revenue is currently derived from a limited set of clients without long-term contracts. * **Wage Inflation:** Rising costs for skilled professionals in the Indian IT and Bio-tech sectors may compress margins during the scaling phase.